Treatment of thrombotic thrombocytopenic purpura

Abstract

The review discusses approaches to treatment of acquired thrombotic thrombocytopenic purpuгa (aTTP). In patients with aTTP plasma exchanges, glucocorticosteroids allow to stop an acute attack of TTP, and use of rituximab allows to achieve remission. In recent years, caplacizumab has been used. Treatment options such as cyclosporin A, bortezomib, splenectomy, N-acetylcysteine, recombinant ADAMTS13 are also described. Separately discussed issues of management of patients with TTP during pregnancy, and pediatric patients with TTP.

Keywords

• adamts13
• thrombotic thrombocytopenic purpura
• pregnancy
• therapeutic plasma exchange
• rituximab
• cyclosporine a
• bortezomib
• n-acetylcysteine
• caplacizumab
• recombinant adamts13